Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Pharmacyclics, Inc.    PCYC   US7169331060


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Pharmacyclics Inks Agreement With Novo Nordisk for Molecule Inhibitor

10/09/2012 | 06:25pm US/Eastern
   By Kristin Jones 

Pharmacyclics Inc. (>> Pharmacyclics, Inc.) has inked an agreement with Novo Nordisk A/S (NVO, NOVO-B.KO) giving the Danish insulin producer rights to certain uses of its Factor VIIa molecule inhibitor, according to a regulatory filing.

Pharmacyclics shares rose 3.75% to $67.20 in after-hours trading. Through the close, the stock had more than doubled in the past six months.

Under the terms of the agreement, Novo Nordisk will acquire the world-wide rights to PCI-27483 for specific noncancer-related uses. The Danish company plans to use it as an excipient in an unnamed product within its biopharmaceutical unit.

An excipient is generally an inactive ingredient used to carry or to add a certain consistency to a drug.

Pharmacyclics has been developing PCI-27483 to inhibit the intracellular signaling involved in tumor growth and to thwart the blood clots that afflict some cancer patients.

The biopharmaceutical company expects to receive an upfront payment of $5 million, as well as up to $55 million based on the achievement of certain development, regulatory and sales milestones. It also will receive royalties on sales of Novo Nordisk products that use PCI-27483.

Novo Nordisk's American depositary shares closed Tuesday at $161.38 and were unchanged after hours. The ADS are up 40% so far this year.

Write to Kristin Jones at

Subscribe to WSJ:

Stocks mentioned in the article : Pharmacyclics, Inc.
Recommend :
React to this article
Latest news on PHARMACYCLICS, INC.
2h ago PHARMACYCLICS : Reports Second Quarter 2014 Results
3h ago PHARMACYCLICS : Results of Operations and Financial Condition, Financial Stateme..
13h ago PHARMACYCLICS : Regulation FD Disclosure, Financial Statements and Exhibits (for..
1d ago PHARMACYCLICS : European Medicines Agency EMA Issues Positive Opinion, Recommend..
3d ago PHARMACYCLICS : Announces Date of Conference call to discuss Financial Results f..
3d ago PHARMACYCLICS : U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two I..
3d agoDJJOHNSON & JOHNSON : Press Release : FDA expands approved use of Imbruvica for ch..
3d ago PHARMACYCLICS : Special Notice - 65-- Emergency Imbruvica Drug Order 140mg/6 Bot..
6d ago PHARMACYCLICS : European Medicines Agency (EMA) Issues Positive Opinion, Recomme..
07/22 PHARMACYCLICS : Justification and Approval - 65-- 506-14-4-021-2516 PHARMACYCLIC..
Duration : Period :
Pharmacyclics, Inc. Technical Analysis Chart | PCYC | US7169331060 | 4-Traders
Income Statement Evolution
Pharmacyclics, Inc. : Income Statement Evolution
More Financials
Dynamic quotes